Kenneth Myszkowski - Arrowhead Pharmaceuticals Chief Officer
| ARWR Stock | USD 26.03 0.12 0.46% |
Executive
Mr. Kenneth Allen Myszkowski is the Chief Financial Officer of Arrowhead Pharmaceuticals, Inc. Mr. Myszkowski joined Arrowhead in 2009. Prior to joining Arrowhead, Mr. Myszkowski served as the corporate controller for Broadwind Energy, a public energy company which provides products and services to the wind energy industry. Previous to his position at Broadwind, Mr. Myszkowski was controller for Epcor USA, the U.S. headquarters for Epcor Utilities, Inc., a public energy company. Prior to Epcor, Mr. Myszkowski was controller for two startup ventures NanoInk, specializing in Dip Pen Nanolithography, a nanofabrication technology, and Delphion, which provided online tools for intellectual property research. Mr. Myszkowski also held several corporate roles at FMC Corporation and Premark International, both Fortune 500 conglomerates. He began his career in the audit practice of Arthur Andersen Co. in Chicago, Illinois since 2010.
| Age | 58 |
| Tenure | 14 years |
| Professional Marks | MBA |
| Address | 177 East Colorado Boulevard, Pasadena, CA, United States, 91105 |
| Phone | 626 304 3400 |
| Web | https://arrowheadpharma.com |
Kenneth Myszkowski Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kenneth Myszkowski against Arrowhead Pharmaceuticals stock is an integral part of due diligence when investing in Arrowhead Pharmaceuticals. Kenneth Myszkowski insider activity provides valuable insight into whether Arrowhead Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Arrowhead Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Arrowhead Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kenneth Myszkowski over six months ago Disposition of 15000 shares by Kenneth Myszkowski of Arrowhead Pharmaceuticals at 36.2 subject to Rule 16b-3 |
Arrowhead Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4072) % which means that it has lost $0.4072 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5184) %, meaning that it created substantial loss on money invested by shareholders. Arrowhead Pharmaceuticals' management efficiency ratios could be used to measure how well Arrowhead Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/01/2024, Return On Tangible Assets is likely to drop to -0.56. In addition to that, Return On Capital Employed is likely to drop to -0.61. At this time, Arrowhead Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 12/01/2024, Non Current Assets Total is likely to grow to about 466.5 M, while Net Tangible Assets are likely to drop slightly above 202.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mark Delong | Apellis Pharmaceuticals | 47 | |
| Anuj MD | Assembly Biosciences | 46 | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| Traci McCarty | Biomarin Pharmaceutical | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Humaira Serajuddin | Biomarin Pharmaceutical | N/A | |
| Jeffrey Ajer | Biomarin Pharmaceutical | 62 | |
| Shikhar MBA | Annexon | N/A | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| Gina JD | Amylyx Pharmaceuticals | 53 | |
| Caroline MD | Apellis Pharmaceuticals | 57 | |
| Lukas MD | Apellis Pharmaceuticals | 53 | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| David Acheson | Apellis Pharmaceuticals | N/A | |
| Steven MD | Incyte | 57 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Linda JD | Wave Life Sciences | N/A | |
| JD Esq | Apellis Pharmaceuticals | 51 | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Jeffrey Eisele | Apellis Pharmaceuticals | 62 | |
| JD Esq | Terns Pharmaceuticals | 55 | |
Management Performance
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.41 |
Arrowhead Pharmaceuticals Leadership Team
Elected by the shareholders, the Arrowhead Pharmaceuticals' board of directors comprises two types of representatives: Arrowhead Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arrowhead. The board's role is to monitor Arrowhead Pharmaceuticals' management team and ensure that shareholders' interests are well served. Arrowhead Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arrowhead Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Kenneth Myszkowski, Chief Officer | ||
| Javier MD, Chief Officer | ||
| Bruce MD, Chief Scientist | ||
| Vincent CFA, Head VP | ||
| MBA MD, Chief Medicine | ||
| Tracie Oliver, Chief Officer | ||
| Aaron Tan, Head Tax | ||
| Christopher Anzalone, CEO and President Director, CEO of Calando, CEO of Tego, CEO of Nantope, CEO of Leonardo and CEO of Ablaris Therapeutics | ||
| PharmD JD, COO Counsel | ||
| Nadia MBA, VP Treasurer | ||
| Howard Lovy, Director Communications | ||
| Mark Davis, Founder Calando | ||
| Mark Seefeld, Head VP |
Arrowhead Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arrowhead Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.41 | ||||
| Operating Margin | (27.85) % | ||||
| Current Valuation | 3.07 B | ||||
| Shares Outstanding | 124.43 M | ||||
| Shares Owned By Insiders | 4.46 % | ||||
| Shares Owned By Institutions | 79.70 % | ||||
| Number Of Shares Shorted | 9.45 M | ||||
| Price To Earning | 482.39 X | ||||
| Price To Book | 17.47 X |
Pair Trading with Arrowhead Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Arrowhead Stock
| 0.37 | BHC | Bausch Health Companies | PairCorr |
| 0.35 | HCM | HUTCHMED DRC | PairCorr |
| 0.32 | GANX | Gain Therapeutics | PairCorr |
The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.
The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.